Amgen Just Walked Away From a Half-Billion-Dollar Bet on T-Cell Therapy

What TScan Keeps (and What It Loses)

The good news for TScan: this isn't a financial emergency. The company keeps the $30 million upfront payment it already received, and there's no early termination penalty. According to its most recent financials, TScan had $100.2 million in cash as of June 30, 2026.

The bad news? All that future upside just evaporated. The $500 million-plus in milestones and the royalty stream are gone unless Amgen or a sublicensee decides to keep developing something that came out of the collaboration. (Don't hold your breath on that one.)

TScan was quick to reassure investors that the termination "does not impact any of the TScan pipelines" and that there are "no planned changes" to its wholly owned programs. That's technically true: the Amgen collaboration was specifically focused on target discovery in Crohn's disease, and TScan's core pipeline lives in oncology. The company's lead program, TSC-101, is currently in a Phase 3 trial (called ALLOHA-2) for blood cancers.

Still, losing a partnership with one of the world's largest biotechs is never a good look, even if the operational impact is contained.

Why Amgen Bailed

Amgen didn't offer much detail beyond its boilerplate portfolio review statement. But the move makes more sense when you zoom out and look at where the company is actually placing its bets.

Amgen's oncology strategy in 2025 and 2026 has been built around bispecific T-cell engagers, or BiTEs. Think of BiTEs as molecular matchmakers: one arm grabs onto a cancer cell, the other arm grabs a T cell, and the two are forced into a blind date that ends badly for the tumor. Amgen's biggest recent success story, IMDELLTRA (tarlatamab), targets small cell lung cancer using this approach. Another BiTE candidate, Xaluritamig, is in development for prostate cancer.

Cell therapy (where you actually engineer a patient's own immune cells and infuse them back) is a fundamentally different game. It's expensive, complex to manufacture, and requires a different kind of infrastructure. Amgen's approach to cell therapy has been selective and partnership-led rather than building a massive in-house program. When you're generating momentum with a BiTE platform that's already producing approved drugs, it's natural to question whether a speculative target-discovery effort in Crohn's disease deserves a seat at the table.

The answer, apparently, was no.

The Bigger Problem: TCR Therapy's Growing Pains

This deal collapse isn't just about Amgen's priorities. It's a window into the broader struggles facing T-cell receptor therapy as a field.

To understand why, you need to know the difference between the two main flavors of engineered T-cell therapy. CAR-T (chimeric antigen receptor T-cell therapy) has been a genuine success story in blood cancers, with multiple FDA-approved products treating leukemia and lymphoma. CAR-T works by recognizing proteins sitting on the surface of cancer cells, like reading a name tag pinned to someone's shirt.

TCR-T (T-cell receptor therapy) takes a different approach. It can recognize proteins that are inside the cell, because those proteins get chopped up and displayed on the cell surface by a molecular system called MHC (major histocompatibility complex). Think of it like reading someone's diary entries that have been posted on their front door. That gives TCR-T a much wider menu of potential targets, which is why researchers are excited about its potential in solid tumors, where surface proteins are harder to find.

But that broader reach comes with a brutal set of trade-offs.

First, there's the HLA restriction problem. The MHC system varies wildly between individuals (it's the same system that determines whether organ transplants get rejected). So a TCR-T therapy that works for patients with one HLA type might be useless for patients with a different type. Every product only fits a fraction of patients, like designing a shoe that only works for left feet.

Second, tumors fight back. Many advanced cancers learn to dial down their MHC expression, essentially taking down the front door so the TCR-T cells can't read anything. It's an elegant escape mechanism, and researchers haven't solved it at scale.

Third, there are real safety concerns. Because TCR-T cells can recognize peptides from normal tissues (not just tumor tissues), off-target toxicity remains a persistent worry. And like CAR-T, TCR-T cells can become exhausted over time, losing their ability to keep fighting.

CAR-T has a head start of several years, multiple approved products, and a clinical track record. TCR-T is still trying to prove it can deliver on its theoretical promise. The field remains scientifically attractive but clinically unproven, especially in the solid tumor setting where it's supposed to shine.

What This Means for TScan

TScan isn't in crisis mode. Its oncology pipeline is independent of the Amgen work, and the Phase 3 ALLOHA-2 trial for TSC-101 continues. The company's TargetScan platform still has value as a discovery engine, and losing one partnership doesn't invalidate the technology.

But the optics matter. When a pharma giant the size of Amgen walks away from your collaboration after a portfolio review, the market notices. It raises questions about whether the targets discovered through the platform were compelling enough to advance, and whether the TCR-based approach to autoimmune disease is ready for prime time.

For a company with $100 million in cash, the pressure to deliver results from its own pipeline just got a little more intense.

The Takeaway

Amgen's exit from the TScan collaboration isn't a death blow to TCR therapy, but it's another data point in a pattern. The engineered T-cell space beyond CAR-T remains full of promise and short on proof. Big pharma companies are willing to write checks for early-stage exploration, but they're also willing to walk away when the strategic math stops working.

TScan still has its platform, its pipeline, and its cash. What it no longer has is a $500 million safety net and the implicit endorsement of one of biotech's biggest names. In this industry, that kind of validation isn't just nice to have; it's the difference between being taken seriously and being overlooked.

The next twelve months will tell us whether TScan can stand on its own. The clock is ticking.

The $2.7 Million Shot That Replaces a Lifetime of Eating Cornstarch

The FDA just approved a $2.7 million one-time gene therapy for a rare metabolic disease that previously had zero approved treatments, only cornstarch eaten on a brutal round-the-clock schedule. Ultragenyx's Genglycos could rewrite the playbook for metabolic gene therapy.